DK1536782T3 - Synergistiske kombinationer af en alfa-2-delta ligand og en PDEV-inhibitor til anvendelse til behandling af smerte - Google Patents
Synergistiske kombinationer af en alfa-2-delta ligand og en PDEV-inhibitor til anvendelse til behandling af smerteInfo
- Publication number
- DK1536782T3 DK1536782T3 DK03787957T DK03787957T DK1536782T3 DK 1536782 T3 DK1536782 T3 DK 1536782T3 DK 03787957 T DK03787957 T DK 03787957T DK 03787957 T DK03787957 T DK 03787957T DK 1536782 T3 DK1536782 T3 DK 1536782T3
- Authority
- DK
- Denmark
- Prior art keywords
- pain
- alpha
- treatment
- synergistic combinations
- delta ligand
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 239000011885 synergistic combination Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0219024.7A GB0219024D0 (en) | 2002-08-15 | 2002-08-15 | Synergistic combinations |
PCT/IB2003/003476 WO2004016259A1 (en) | 2002-08-15 | 2003-08-04 | Synergistic combination of an alpha-2-delta ligand and a pdev inhibitor for use in the treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1536782T3 true DK1536782T3 (da) | 2007-07-30 |
Family
ID=9942388
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03787957T DK1536782T3 (da) | 2002-08-15 | 2003-08-04 | Synergistiske kombinationer af en alfa-2-delta ligand og en PDEV-inhibitor til anvendelse til behandling af smerte |
Country Status (40)
Country | Link |
---|---|
EP (1) | EP1536782B1 (da) |
JP (1) | JP2006502139A (da) |
KR (2) | KR20050042154A (da) |
CN (1) | CN1674884A (da) |
AP (1) | AP2005003227A0 (da) |
AR (1) | AR040871A1 (da) |
AT (1) | ATE359775T1 (da) |
AU (1) | AU2003249476B2 (da) |
BR (1) | BR0313484A (da) |
CA (1) | CA2495433A1 (da) |
CR (1) | CR7687A (da) |
DE (1) | DE60313330T2 (da) |
DK (1) | DK1536782T3 (da) |
EA (1) | EA007504B1 (da) |
EC (1) | ECSP055593A (da) |
ES (1) | ES2285230T3 (da) |
GB (1) | GB0219024D0 (da) |
GE (1) | GEP20084366B (da) |
GT (1) | GT200300173A (da) |
HN (1) | HN2003000247A (da) |
HR (1) | HRP20050136A2 (da) |
IL (1) | IL166415A0 (da) |
IS (1) | IS7643A (da) |
MA (1) | MA27381A1 (da) |
MX (1) | MXPA05001835A (da) |
NO (1) | NO20050782L (da) |
NZ (1) | NZ537818A (da) |
OA (1) | OA12899A (da) |
PA (1) | PA8577301A1 (da) |
PE (1) | PE20040992A1 (da) |
PL (1) | PL375553A1 (da) |
PT (1) | PT1536782E (da) |
RS (1) | RS20050078A (da) |
SI (1) | SI1536782T1 (da) |
TN (1) | TNSN05042A1 (da) |
TW (1) | TW200404531A (da) |
UA (1) | UA77329C2 (da) |
UY (1) | UY27936A1 (da) |
WO (1) | WO2004016259A1 (da) |
ZA (1) | ZA200500369B (da) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NI200300043A (es) | 2002-03-28 | 2003-11-05 | Warner Lambert Co | AMINOACIDOS CON AFINIDAD POR LA PROTEINA a2DELTA. |
CA2538412A1 (en) * | 2003-09-12 | 2005-03-24 | Warner-Lambert Company Llc | Combination comprising an alpha-2-delta ligand and an ssri and/or snri for treatment of depression and anxiety disorders |
WO2005030184A2 (en) | 2003-09-25 | 2005-04-07 | Warner-Lambert Company Llc | Therapeutic beta aminoacids |
MXPA06003395A (es) * | 2003-09-25 | 2006-06-08 | Warner Lambert Co | Aminoacidos con afinidad por la proteina a2d. |
GB0405200D0 (en) * | 2004-03-08 | 2004-04-21 | Pfizer Ltd | Combinations comprising alpha-2-delta ligands |
BRPI0513028A (pt) * | 2004-07-09 | 2008-04-22 | Warner Lambert Co | preparação de beta-aminoácidos tendo afinidade para a proteìna alfa-2-delta |
ITMI20041447A1 (it) * | 2004-07-20 | 2004-10-20 | Zambon Spa | Composizione farmaceutica comprendente gabapentina |
US20090227562A1 (en) * | 2004-08-10 | 2009-09-10 | Pfizer Inc. | Combination of a Selective Noradrenaline Reuptake Unhibitor and a PDEV Inhibitor |
JP2008512436A (ja) * | 2004-09-07 | 2008-04-24 | ファイザー・インク | 片頭痛治療用の5−HT(1)受容体アゴニストとα2δリガンドの組み合わせ |
WO2006092692A1 (en) * | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of combinations of pde7 inhibitors and alpha-2-delty ligands for the treatment of neuropathic pain |
BRPI0810773A2 (pt) * | 2007-04-30 | 2014-10-07 | Adolor Corp | Composição farmacêutica, métodos para tratar dor em um mamífero, para tratar depressão em um mamífero, para tratar um distúrbio em um paciente, para fabricar um composto, e para inibir a captação de norepinefrina, composto, e, uso de uma composição. |
WO2008132589A1 (en) * | 2007-05-01 | 2008-11-06 | Pfizer Limited | Combinations comprising pregabalin |
US20090148532A1 (en) * | 2007-12-06 | 2009-06-11 | Venkatesh Gopi M | Preparation of controlled release skeletal muscle relaxant dosage forms |
TWI531362B (zh) | 2008-07-21 | 2016-05-01 | 艾爾康股份有限公司 | 具有治療劑遞送能力之眼科裝置 |
AU2011283462B9 (en) | 2010-07-30 | 2014-09-18 | Toray Industries, Inc. | Therapeutic agent or prophylactic agent for neuropathic pain |
CN103717602B (zh) | 2011-05-17 | 2016-11-09 | 加利福尼亚大学董事会 | 激酶抑制剂 |
PL2710005T3 (pl) | 2011-05-17 | 2017-07-31 | Principia Biopharma Inc. | Inhibitory kinazy tyrozynowej |
US9376438B2 (en) | 2011-05-17 | 2016-06-28 | Principia Biopharma, Inc. | Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors |
WO2013084182A1 (en) * | 2011-12-08 | 2013-06-13 | Glenmark Pharmaceuticals S.A. | Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent |
RS58956B1 (sr) | 2012-09-10 | 2019-08-30 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
ES2841248T3 (es) | 2014-02-21 | 2021-07-07 | Principia Biopharma Inc | Sales y forma sólida de un inhibidor de BTK |
PT3233103T (pt) | 2014-12-18 | 2021-01-18 | Principia Biopharma Inc | Tratamento de pênfigo |
MA42242A (fr) | 2015-06-24 | 2018-05-02 | Principia Biopharma Inc | Inhibiteurs de la tyrosine kinase |
KR102515813B1 (ko) | 2016-06-29 | 2023-03-30 | 프린시피아 바이오파마, 인코퍼레이티드 | 2-[3-[4-아미노-3-(2-플루오로-4-페녹시-페닐)피라졸로[3,4-d]피리미딘-1-일]피페리딘-1-카르보닐]-4-메틸-4-[4-(옥세탄-3-일)피페라진-1-일]펜트-2-엔니트릴의 변형 방출 제제 |
CN114195661B (zh) * | 2021-12-21 | 2023-12-22 | 苏州楚凯药业有限公司 | 一种苯磺酸米洛巴林的制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100491282B1 (ko) * | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
JP2002508362A (ja) * | 1997-12-16 | 2002-03-19 | ワーナー−ランバート・カンパニー | 1−置換−1−アミノメチル−シクロアルカン誘導体(=ガバペンチン類縁体)、その製造および神経学的疾患の治療におけるその使用 |
HN2000000224A (es) * | 1999-10-20 | 2001-04-11 | Warner Lambert Co | Aminoacidos biciclicos como agentes farmaceuticos |
IL152925A (en) * | 1999-10-21 | 2010-04-15 | Pfizer | Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin |
CN1471397A (zh) * | 2000-08-30 | 2004-01-28 | 利利艾科斯有限公司 | 治疗偏头痛的方法 |
EA006396B1 (ru) * | 2001-04-19 | 2005-12-29 | УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл Эл Си | Конденсированные бициклические аминокислоты |
-
2002
- 2002-08-15 GB GBGB0219024.7A patent/GB0219024D0/en not_active Ceased
-
2003
- 2003-04-08 UA UAA200501347A patent/UA77329C2/uk unknown
- 2003-07-11 PA PA20038577301A patent/PA8577301A1/es unknown
- 2003-08-04 DK DK03787957T patent/DK1536782T3/da active
- 2003-08-04 OA OA1200500037A patent/OA12899A/en unknown
- 2003-08-04 JP JP2004528754A patent/JP2006502139A/ja not_active Withdrawn
- 2003-08-04 EA EA200500207A patent/EA007504B1/ru not_active IP Right Cessation
- 2003-08-04 CA CA002495433A patent/CA2495433A1/en not_active Abandoned
- 2003-08-04 WO PCT/IB2003/003476 patent/WO2004016259A1/en active IP Right Grant
- 2003-08-04 BR BR0313484-9A patent/BR0313484A/pt not_active IP Right Cessation
- 2003-08-04 AU AU2003249476A patent/AU2003249476B2/en not_active Ceased
- 2003-08-04 IL IL16641503A patent/IL166415A0/xx unknown
- 2003-08-04 PL PL03375553A patent/PL375553A1/xx not_active Application Discontinuation
- 2003-08-04 MX MXPA05001835A patent/MXPA05001835A/es active IP Right Grant
- 2003-08-04 GE GEAP8632A patent/GEP20084366B/en unknown
- 2003-08-04 KR KR1020057002450A patent/KR20050042154A/ko not_active Application Discontinuation
- 2003-08-04 ES ES03787957T patent/ES2285230T3/es not_active Expired - Lifetime
- 2003-08-04 RS RSP-2005/0078A patent/RS20050078A/sr unknown
- 2003-08-04 NZ NZ537818A patent/NZ537818A/en unknown
- 2003-08-04 CN CNA038190737A patent/CN1674884A/zh active Pending
- 2003-08-04 AP AP2005003227A patent/AP2005003227A0/xx unknown
- 2003-08-04 EP EP03787957A patent/EP1536782B1/en not_active Expired - Lifetime
- 2003-08-04 AT AT03787957T patent/ATE359775T1/de not_active IP Right Cessation
- 2003-08-04 DE DE60313330T patent/DE60313330T2/de not_active Expired - Fee Related
- 2003-08-04 PT PT03787957T patent/PT1536782E/pt unknown
- 2003-08-04 KR KR1020077000033A patent/KR20070009746A/ko not_active Application Discontinuation
- 2003-08-04 SI SI200330810T patent/SI1536782T1/sl unknown
- 2003-08-12 UY UY27936A patent/UY27936A1/es not_active Application Discontinuation
- 2003-08-12 PE PE2003000806A patent/PE20040992A1/es not_active Application Discontinuation
- 2003-08-13 AR AR20030102933A patent/AR040871A1/es not_active Application Discontinuation
- 2003-08-14 TW TW092122363A patent/TW200404531A/zh unknown
- 2003-08-14 GT GT200300173A patent/GT200300173A/es unknown
- 2003-08-14 HN HN2003000247A patent/HN2003000247A/es unknown
-
2005
- 2005-01-12 IS IS7643A patent/IS7643A/is unknown
- 2005-01-14 ZA ZA200500369A patent/ZA200500369B/en unknown
- 2005-02-10 EC EC2005005593A patent/ECSP055593A/es unknown
- 2005-02-14 HR HR20050136A patent/HRP20050136A2/xx not_active Application Discontinuation
- 2005-02-14 CR CR7687A patent/CR7687A/es not_active Application Discontinuation
- 2005-02-14 NO NO20050782A patent/NO20050782L/no not_active Application Discontinuation
- 2005-02-15 MA MA28104A patent/MA27381A1/fr unknown
- 2005-02-15 TN TNP2005000042A patent/TNSN05042A1/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1536782T3 (da) | Synergistiske kombinationer af en alfa-2-delta ligand og en PDEV-inhibitor til anvendelse til behandling af smerte | |
IL166780A0 (en) | Use of ikappab-kinase inhibitors in pain therapy | |
DK1519770T3 (da) | Elektroporesisk indretning og indsprøjtningsapparat | |
IS7434A (is) | N-amínóasetýl-pýrrólídín-2-karbónítríl og notkun þeirra sem DDP-IV tálma | |
DK1606283T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
IS8037A (is) | P38-hindrar og aðferðir til notkunar þeirra | |
NO20041872L (no) | Esterforbindelser og medisinsk anvendelse derav | |
NO20031481D0 (no) | Anordning som assisterer trekking på jevne og ujevne overflater | |
EP1763490A4 (en) | ELECTRODEIONIZATION DEVICE AND USE METHOD | |
DK1487541T3 (da) | Anvendelse af IL-18-inhibitorer til behandling og/eller forebyggelse af perifere vaskulære sygdomme | |
PL374598A1 (en) | Caspase inhibitors and uses thereof | |
ZA200509700B (en) | Caspase inhibitors and uses thereof | |
IL177709A0 (en) | Caspase inhibitors and uses thereof | |
CY2013031I1 (el) | Χρηση διϋδροϊμιδαζολονων για την αγωγη της επιληψιας στους σκυλους | |
AU2003211009A8 (en) | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors | |
IS7417A (is) | Ambroxól til að meðhöndla kvalafullt ástand í munni og koki | |
IS8390A (is) | Notkun á gaboxadóli við meðhöndlun á svefnleysi | |
AU2003206945A8 (en) | Use of proteinase inhibitors in the treatment of autoimmune diseases | |
NO20055668D0 (no) | Beta-amyloidinhibitorer og anvendelse derav | |
EP1539781A4 (en) | RSK inhibitors and their therapeutic applications | |
SG110107A1 (en) | Compound and use in treatment | |
EP1467673A4 (en) | IRRIGATION SOLUTION AND METHODS OF USE | |
GB0411145D0 (en) | Protease inhibitors and their therapeutic applications | |
DE602004017166D1 (de) | Gabapentintannat in flüssigen und/oder halbfesten dosierformen | |
AU2003238948A8 (en) | Caspase-1 inhibitors and methods for their use |